Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Clinical trial NCT06726148 · RECRUITING

Trial details

NCT number: NCT06726148
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced HR+/HER2- Breast Cancer Advanced CCNE1-amplified Solid Tumors Extensive-stage Small Cell Lung Cancer

Start date: 2025-04-03
Primary completion: 2028-09-25
Enrollment: 280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.